LMR Partners’s Crescent Biopharma CBIO Stock Holding History

LMR Partners’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-5	Closed	-$141	–	1376
2024 Q2	$141	Buy	+5	New	+$520	﹤0.01%	1084

Other funds holding CBIO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

LMR Partners's CBIO Position: Q3 2024 in Review

LMR Partners sold out of Crescent Biopharma (CBIO) in Q3 2024, closing a stake of 141 shares — an estimated $3.97K sold.

LMR Partners first reported a position in CBIO in Q2 2014 and held it in 7 quarters. The position peaked at $166K in Q2 2014. 36 funds tracked by Wall St. Rank hold CBIO as of Q3 2024.

LMR Partners reported no remaining Crescent Biopharma position as of Q3 2024 after selling out during the quarter.
LMR Partners sold 141 Crescent Biopharma shares in Q3 2024, an estimated $3.97K.
LMR Partners first reported a position in Crescent Biopharma in Q2 2014 and held it in 7 quarters.
LMR Partners's Crescent Biopharma position peaked at $166K in Q2 2014.
36 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2024.

Based on LMR Partners's 13F filing for Q3 2024, filed 7 Nov 2024.